The tumor suppressor, PTEN, is one of the most commonly mutated genes in cancer. Recently, PTEN has been shown to localize in the nucleus and is required to maintain genomic stability. Here, we show that nuclear PTEN, independent of its phosphatase activity, is essential for maintaining heterochromatin structure. Depletion of PTEN leads to loss of heterochromatic foci, decreased chromatin compaction, overexpression of heterochromatic genes, and reduced protein stability of heterochromatin protein 1 a. We found that the C-terminus of PTEN is required to maintain heterochromatin structure. Additionally, cancer-associated PTEN mutants lost their tumor-suppressor function when their heterochromatin structure was compromised. We propose that this novel role of PTEN accounts for its function in guarding genomic stability and suppressing tumor development.
Introduction
PTEN (phosphatase and tensin homolog deleted from chromosome 10), a tumor suppressor gene, is frequently mutated in a number of tumor lineages, including: glioblastomas, melanomas, and carcinomas of the prostate, breast, and endometrium. [1] [2] [3] PTEN has been known to regulate AKT kinase activation as well as downstream cell survival and growth response and is dependent upon its phosphatase activity. [4] [5] [6] Intriguingly, recent studies have identified PTEN localization in the nucleus, through monoubiquitination by NEDD4-1, 7 where it interacts with nuclear proteins and is required for maintaining genomic stability. 8, 9 This is mediated partly independently of the PI3K-AKT pathway. Additionally, PTEN has been found to localize at centromeres, and the disruption of the association of PTEN with centromeres was found to cause centromeric instability. 8 Nevertheless, how nuclear PTEN regulates the centromere and other nuclear components remains elusive.
The mammalian centromere and pericentromere is composed of a distinct compact chromatin structure, called heterochromatin, which is essential for proper centromere stability and function. 10, 11 The heterochromatin is constructed by epigenetic modifications, such as repressive histone H3 trimethyl Lys 9 (H3K9me3), histone hypoacetylation, and by accumulation of non-histone protein heterochromatin protein 1 (HP1), which recruits other essential downstream heterochromatin modifying proteins. [12] [13] [14] [15] Embedded in the heterochromatin is a group of highly repetitive DNA sequence, referred to as satellite DNA. 14, 16 Transcription of satellite DNA is naturally repressed by the compact structure of heterochromatin; thus, its overexpression has been associated with genomic instability. 17, 18 The implications of heterochromatin structure in human cancer have been recently highlighted by the dramatic correlation between the mutation rates of the cancer genome and heterochromatin, 19 and by the overexpression of heterochromatic satellite DNA sequence in diverse mouse and human cancers. 20 In the present study, we identify a link between PTEN and heterochromatin. We demonstrate that PTEN plays an essential role in maintaining heterochromatin structure through the C-terminus domain, which is independent of its phosphatase activity. The cancer-associated PTEN mutant that is devoid of its C-terminus lost its tumor-suppressive function, which reveals a new mechanism for PTEN in guarding genomic stability and thus tumor suppression.
Results
Heterochromatin structure is impaired by PTEN deficiency Recently, PTEN was found to be critical for the stability of centromeres, 8 which led us to explore the role of PTEN in the regulation of heterochromatin structure. We found that in mouse embryonic fibroblast (MEF) cells, PTEN knockout led to a significant reduction in H3K9me3 foci intensity, indicative of decondensation of the heterochromatin (Fig. 1A) . Tight heterochromatin structure was reformed upon addition of wild-type (WT) PTEN. Additionally, reduction in H3K9me3 foci was also detected when PTEN expression was transiently knocked down in human U2OS cells ( Fig. 1B) , revealing a common regulatory role of PTEN in heterochromatin in both mouse and human cell lines. In contrast, the euchromatin marker histone 3 lysine 4 dimethylation (H3K4me2) was unaffected by the loss of PTEN ( Fig. S1) .
Defects in heterochromatin can result in the overexpression of the embedded genes. 21 The peri-and centromere heterochromatin consist of highly repetitive DNA elements, major and minor DNA satellites in mice 14 and Satellite a (Sata) and mcBox DNA in humans. 16 To determine the functional consequence of heterochromatin, we performed quantitative real time PCR (RT-qPCR) to examine the transcription of satellite DNA. The overexpression of both mouse and human satellite DNA was detected in the absence of PTEN ( Fig. 1C & D) . Along with the increased satellite transcription, PTEN knockout also decreased the enrichment of H3K9me3 at the satellite locus ( Fig. 1E ). This suggested that the absence of PTEN resulted in the loss of chromatin compaction. To test this hypothesis, a micrococcal nuclease (MNase) digestion assay was performed. MNase cleaves preferentially the linker DNA that lies between individual nucleosomes, thus the sensitivity of the genomic DNA to MNase reflects the condensation of the chromatin. We discovered that the genomic DNA extracted from PTEN-depleted cells was highly sensitive to MNase (Fig. 1F left) . Similar results were found in U2OS cells treated with PTEN siRNA (Fig. 1F right) . These findings leads us to believe that PTEN may be essential in maintaining the compact nature of heterochromatin and consequently, to suppress the transcription of heterochromatic genes. 
PTEN regulates heterochromatin structure by binding and stabilizing HP1a
The heterochromatin defects in PTEN-depleted mouse and human cells highlights a fundamental role of PTEN in stabilizing heterochromatin structure. To gain mechanistic insight into the role of PTEN in maintaining heterochromatin structure, we investigated whether PTEN directly associates with heterochromatin. A chromatin fractionation assay revealed that PTEN was able to bind directly to chromatin ( Fig. S2A ). Furthermore, a chromatin immunoprecipitation assay (ChIP) showed that PTEN was enriched on the heterochromatin Sata DNA (Fig. S2B) . The enrichment of PTEN on heterochromatin seemed independent of the histone code because no interaction between PTEN and H3K9me3 could be detected (unpublished observations).
Since PTEN binds directly to heterochromatin, we then sought to determine if PTEN was also able to interact with other heterochromatin proteins. HP1 is a major component of heterochromatin. HP1 acts as a structural adaptor by mediating the formation of stable macromolecular complexes between nucleosomes and thus plays a key role in establishing and maintaining transcriptionally repressive heterochromatin. 22, 23 Through coimmunoprecipitation (co-IP) assays, we found that PTEN binds to HP1a ( Fig. 2A & B) . Moreover, in an in vitro binding experiment, PTEN was able to weakly bind to HP1a, in the absence of all other cellular protein ( Fig. 2C) . Additionally, this interaction was derived from only nuclear PTEN ( Fig. 2D ).
Since the binding affinity of PTEN to HP1a was significantly higher in the presence of cellular proteins, PTEN and HP1a may be part of a complex that binds to heterochromatin. Furthermore, endogenous PTEN and endogenous HP1a bind together in the nucleus in WT MEF cells ( Fig. 2E ). Next, we assessed whether PTEN functionally regulates HP1a. In PTEN knockout cells, HP1a protein level was significantly reduced (Fig. 2F) , however, no change in HP1a mRNA level was observed in both PTEN knockout and PTEN knockdown cells ( Fig. S2C, D) . Moreover, a dramatic reduction of HP1a foci intensity was observed in PTEN-knockout MEF cells compared to WT MEF cells ( Fig. 2G ) Thus, PTEN is required for heterochromatin structure.
PTEN regulates the function of HP1a by a directional binding interaction and this is reflected in the expression level of these proteins. Since the cell cycle is dependent upon the change in HP1a's cellular distribution, 24 we investigated the cell cycle distribution in both PTEN knockdown and knockout cells. We found that cell cycle only slightly changed in PTEN deficient cells ( Fig. S3 ). In addition, treatment with the PI3K inhibitor, LY294002 (LY), in PTEN knockdown cells showed that the downregulation of HP1a was independent of the PI3K-AKT pathway (Fig. 2H) . Furthermore, the treatment of U2OS cells with LY did not change the expression level of HP1a (Fig. S4A) . The stability of HP1a was assessed in both PTEN WT and knockout cells. We observed that in PTEN deficient cells, the half-life of HP1a was reduced from 24 h to 6 h ( Fig. 2I) , implying that PTEN stabilizes HP1a. Moreover, treatment with the proteasome inhibitor, MG132, increased the expression level of HP1a in PTEN deficient cells, suggesting that HP1a was degraded through the proteasome pathway ( Fig. 2J ). Increased polyubiquitination of HP1a was also observed in PTEN-knockdown cells ( Fig. 2K) , which supports our hypothesis that PTEN protects HP1a from degradation. Additionally, the introduction of HP1a suppressed the satellite DNA overexpression in PTENknockdown cells ( Fig. 2L) , indicating that the decrease in HP1a expression is directly related to defects in the heterochromatin when PTEN expression is also depleted. Together, the above observations indicate that PTEN localizes to heterochromatin and, by stabilizing HP1a from proteasomal degradation, is essential to maintain the compact heterochromatin structure.
The C-terminus of PTEN is critical for maintaining heterochromatin structure
Previous studies have shown that the C-terminus has a functional role in nuclear localization, anchorage-independent growth and cell migration. 9 Moreover, in patients with Cowden Syndrome, which are highly susceptible to breast and thyroid cancer, 80% of their total mutations are germline C-terminus PTEN truncations. 25 Therefore, using the overexpression of satellite DNAs as a reporter of disrupted heterochromatin, we conducted a knockdown-and-mutant-rescue experiment to examine the function of various cancer-associated PTEN mutants in heterochromatin. As determined by RT-qPCR, WT PTEN successfully suppressed satellite DNA overexpression (Fig. 3A) , confirming that PTEN is directly involved in maintaining heterochromatin structure. Furthermore, phosphatase-dead PTEN mutants (C124S, R130G/Q and R173C) showed rescue effects comparable to those of WT PTEN, which further demonstrated that PTEN maintains normal heterochromatin structure independent of its phosphatase activity. Interestingly, we discovered that the C-terminal truncated mutant, PTEN Y336*, which retains the intact N-terminal phosphatase domain and AKT activity (as shown in Fig. S4B ), not only failed to suppress satellite DNA overexpression but also increased its transcription »20-fold ( Fig. 3A lower panel) . This dramatic satellite DNA upregulation prompted us to explore how this C-terminus truncated mutant affects the heterochromatin structure.
As the overexpression of HP1a can repress satellite DNA expression in PTEN-knockout cells (Fig. 2L) , we reasoned that the high expression level of the satellite DNA with the introduction of the PTEN Y336* mutant was due to an altered HP1a expression level. Indeed, HP1a protein stability was significantly decreased in the PTEN Y336* mutant cells ( Fig. 3B) , with a 5 h half-life of HP1a, which is comparable to the PTEN knockout cells (see Fig. 2I ). Moreover, the PTEN Y336* mutant had enhanced polyubiquitination of HP1a (Fig. 3C ). This indicates that the truncated PTEN mutant does not stabilize HP1a from degradation, and as a consequence, the heterochromatin structure may be compromised.
Next, we determined if the effect of the PTEN Y336* mutant on HP1a was caused by an altered binding affinity to heterochromatin. The co-IP showed that the PTEN Y336* mutant was able to bind to HP1a, and the enrichment of the PTEN Y336* mutant was detected at the Sata locus ( Fig. S5A, B) . These results suggested that the lack of Sata transcription-repressive activity was not due to the reduced association of PTEN Y336* with heterochromatin. In contrast to the predominantly cytosolic localization of WT PTEN, the PTEN Y336* mutant accumulates predominantly in the nucleus (Fig. 3D) . This observation of the nuclear distribution of PTEN Y336* allowed us to hypothesize that this mutant interferes with the normal heterochromatin function of PTEN. To test this idea, we co-transfected PTEN Y336* with WT PTEN or vector control. In the presence of both WT PTEN and PTEN Y336*, the abundance of nuclear WT PTEN was greatly reduced compared to the WT PTEN and vector control (Fig. 3E) . Next, we conducted co-IP experiments to examine the interaction of WT PTEN with HP1a in the presence of the PTEN Y336* mutant. BT549 cells expressing WT PTEN (BT549 PTEN), Vector control (BT549 Vet), or PTEN Y336* (PT549 336*) were transfected with HA-PTEN WT (HA-PTEN), HA-vet, or HA-PTEN Y336* (HA-336*). A co-IP was performed with anti-HA antibody and probed for PTEN and HP1a. Interestingly, we found that a weak complex formed between the WT and PTEN Y336* mutant ( Fig. 3F) and PTEN 336* was also shown to bind to HP1a. Due to the complex formation of WT PTEN and PTEN Y336*, interaction between WT PTEN and HP1a was diminished which was likely due to the reduction of nuclear WT PTEN.
C-terminal truncated PTEN mutant does not function as a tumor suppressor and is sensitive to chemotherapeutic agents
To investigate how PTEN's stabilization of HP1a effects its tumor-suppressive role, we compared the cell growth and colony formation in PTEN-null breast cancer cell line BT-549, which was reconstituted with either an empty control vector, WT PTEN, PTEN Y336* mutant, or WT PTEN with HP1a knockdown (PTEN-HP1aKD). In contrast to WT PTEN, both the PTEN Y336* and PTEN-HP1aKD mutants failed to suppress cell growth (Fig. 4A) , arrest cell-cycle progression (Fig. 4B) , or inhibit colony formation in a soft agar assay (Fig. 4C) . Both mutants responded similarity to the empty vector control in cell proliferation, cell cycle arrest and colony formation, indicating the loss of its tumor suppressor function.
Since PTEN-deficient cancer cells are hypersensitive to DNAdamaging agents, 26 we next examined the response of the reconstituted PTEN cell lines to the genotoxic agent, doxorubicin. We found that the WT PTEN cells exhibited decreased sensitivity to doxorubicin, whereas the PTEN Y336* and PTEN-HP1aKD mutants, and the empty control vector cells exhibited similar sensitivity to doxorubicin (Fig. 4D) .
Loss of PTEN compromises homologous recombination repair and thus PTEN-null cancer cells are more sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. 27 In agreement, we determined that WT PTEN cells displayed decreased sensitivity to the PARP inhibitor, BMN673. However, similar sensitivity to BMN673 was observed in control and both PTEN Y336* and PTEN-HP1aKD mutant reconstituted BT-549 cells (Fig. 4E) . Doxorubicin and PARP inhibitors target highly proliferating cells by inhibiting DNA replication or DNA damage repair, respectively. Therefore, we included a DNA-demethylating agent, 5-aza-2 0 -deoxycytidine (5-AZA), which was recently shown to be an effective chemotherapeutic agent in satellite DNA overexpressing cells. 28 Interestingly, we discovered that only WT PTEN cells had reduced sensitivity to 5-AZA (Fig. 4F) .
Lastly, to determine the relevance of the regulation of HP1a by PTEN in human patients, immunohistochemistry staining of HP1a and PTEN were conducted on breast cancer tissue microarrays (Fig. 4G) . Expression correlation between HP1a and PTEN was detected in 6 individual breast carcinoma samples. Interestingly, in grade 1 tumors, which consist of well-differentiated slow growing tumor cells, PTEN and HP1a expression was increased, whereas in grade 2 tumors, comprising of moderately-differentiated cells PTEN and HP1a are decreased. These data indicated that PTEN and HP1a are highly correlated in normal and breast cancer tissues suggesting that loss of PTEN may contribute to loss of HP1a in advanced human tumors. Thus, in breast cancer tumors, PTEN deficiency also leads to decrease in HP1a expression that results in the relaxation of heterochromatin and may led to the further dysregulation of the embedded heterochromatic genes. 
Discussion
At the time of submission, Chen et al. reported that PTEN interacts with histone H1 and together with HP1a, repressed H4K16 acetylation and maintained chromatin condensation. 29 Together with our report, we propose that PTEN has a critical role in the maintenance of heterochromatin by forming a complex with HP1a and histone H1 for chromatin condensation. In the absence of PTEN, the heterochromatin relaxes, activating transcription of the embedded genes. PTEN binds to HP1a, therefore stabilizing HP1a from degradation from the proteasomal pathway. Moreover, the C-terminus of PTEN is essential for maintaining heterochromatin structure. However, cancer associated PTEN mutants that have an active phosphatase domain, most notably PTEN Y336*, despite still being able to bind to HP1a was unable to stabilize and protect HP1a from degradation. Instead, a 20-fold increased satellite DNA expression was observed, indicating the disruption of heterochromatin structure and the lost of PTEN's suppressive function. Nevertheless, in PTEN deficient BT549 cells, the expression of Y336* had no effect of HP1a stability (Fig. S5B) . We suggest that the PTEN Y336* mutant may act in a dominant-negative manner to suppress PTEN function on heterochromatin, possibly by directly interacting with WT PTEN and thus affecting nuclear accumulation of PTEN.
Due to the relaxed nature of heterochromatin when PTEN is absent or has a C terminus truncation (PTEN 336*), patients with this phenotype may be more responsive to chemotherapies. Our results showed that breast cancer cells expressing C-terminal truncated PTEN mutants are as sensitive to the DNA-damaging drug, doxorubicin, a PARP inhibitor, BMN673, and a DNAdemethylating agent, 5-AZA, as PTEN-deficient breast cancer cells. This indicates that these chemotherapeutic drugs can be equally useful in treating C-terminal truncated PTEN as well as PTEN-deficient tumors. However, since the phosphatase activity is still intact in the C-terminal truncated PTEN mutants, this mutant can still suppress AKT activity and thus are unlikely to respond to either PI3K or AKT inhibitor treatment (unpublished observation). Therefore, we propose that the combination of PTEN mutational analysis and satellite DNA expression pattern may be utilize to develop a chemotherapeutic strategy, in which patients may benefit from treatment with DNA-damaging agents. In addition, the decreased in HP1a expression level was correlated with progression of many human cancers, including breast, brain, colon, leukemia and papillary thyroid cancers. 30 In this sense, the potential importance of satellite DNA, HP1a and PTEN dysregulation as a biomarker in cancer progression merits further clinical testing.
Methods
Cell culture and reagents U2OS and MCF10A cells were purchased from American Type Culture Collection (ATCC). U2OS cells were maintained in McCoy 5A medium supplemented with 10% FBS. MCF10A cells were cultured in mammary epithelial growth medium containing insulin, hydrocortisone, EGF, and bovine pituitary extract purchased from Clonetics. PTEN WT and PTEN knockout MEF cells were kindly provided by Dr. Hui-Kuan Lin and were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS. Transfection reagents Lipofectamine 2000 and Lipofectamine 3000 were purchased from Life Technologies. FuGENE Ò 6 Transfection Reagent was purchased from Promega.
Cell proliferation assays
Cells were seeded in 96-well plates (200 cells/well) and incubated for a total of 5 d at 37 C, 5% CO 2 . MTT assays were performed. The absorbance was measured at 570 nm using a microplate reader (Molecular Devices). The proliferation rate was calculated relative to that for control cells.
Cell fractionation and immunoprecipation
Cell fractionation assays were performed using NP-40 as previously described. 31 To obtain cytosolic and nuclear fractions, cells were harvested in PBS and centrifuged at 500 £ g for 5 min at 4 C. The supernatant was discarded and the cell pellet was resuspended in 100 mLof fractionation buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 0.2% Nonidet P-40 (NP-40), supplemented with a protease inhibitors cocktail. Following centrifugation at 1000 £ g for 5 min, the supernatant was collected and regarded as cytosolic fraction. The pellet was washed with the same buffer without NP-40. After washing, the pellets were collected by centrifugation at 1000 £ g for 5 min, and regarded as nuclear fraction. To precipitate the endogenous PTEN, whole-cell extracts, cytosolic and nuclear extracts obtained from MEF cells were pre-cleared with protein A/G plus-agarose beads (Santa Cruz) and 1mg mouse IgG (Santa Cruz). Then, cellular extracts were subjected to incubation with PTEN antibody (Millipore #04-035) overnight and incubated with protein A/G agarose beads for 4 h at 4 C. The immunocomplex was eluted in loading buffer by boiling at 95 C for 5 min and then subject to WB analysis.
Immunoprecipitation U2OS cells transiently transfected with Flag-tagged or HAtagged plasmids and incubated at 37 C, 5% CO 2 for 48 h. Whole-cell extracts were prepared with lysis buffer (25 mM Tis. HCl PH7.4, 150 mM NaCl, 5% Glycerol, 1% NP40, 1 mM EDTA) and pre-cleared with protein A/G plus-agarose beads (Santa Cruz) and 1mg mouse IgG (Santa Cruz). The cellular extracts were incubated with anti-FlagM2 affinity gel (Sigma-Aldrich #A2220) or anti-HA¡agarose (Sigma-Aldrich #A2095) overnight, and then incubated with protein A/G agarose beads for 4 h at 4 C. The immunocomplex was eluted in loading buffer by boiling at 95 C for 5 min and then subject to WB analysis.
Cell Viability
Cells were seeded in 96-well plates (200 cells/well) and incubated overnight at 37 C, 5% CO 2 . Cells were then treated with DMSO control or indicating concentrations of BMN673 (Selleckchem), doxorubicin (Selleckchem), or 5-aza-2 0 -deoxycytidine (Selleckchem) and incubated for 5 d at 37 C, 5% CO 2 . MTT assays were performed. The absorbance was measured at 570 nm using a microplate reader (Molecular Devices). The cell viability was calculated relative to control cells.
Direct binding Interaction
GST-vector and GST-HP1a bacterial constructs were grown to an OD 600 of 0.8 at 37 C and induced with 0.1 mM IPTG. Cultures were incubated overnight at 37 C. The cells were pelleted and resuspended in PBS lysis buffer (150 mM NaCl, 20 mM NaHPO 4 , 1 % trition-100, protease inhibitors). The samples were sonicated (10 puluses, 2£) and centrifuged at 12,000 £ g for 15 min at 4 C. The supernatant was transferred to a new tube and incubated with glutathione-sepharose beads for 30 min at 4 C, rotating. The samples were centrifuged at 750 £ g for 1 min at 4 C and supernatant was removed. The beads were washed twice with 5 mL PBS (150 mM NaCl, 20 mM NaHPO 4 , protease inhibitors) and centrifuged at 750 £ g for 1 min at 4 C. Recombinant PTEN was made using TnT Quick Coupled Transcription/Translation System (Promega) with pFLAG-PTEN according to the manufacturer's protocol. GST-vector, GST-HP1a, and PTEN was quantified through western blot analysis. Direct binding interaction was determined by incubating GST-HP1a with PTEN in PBS buffer (see above) for 2 h at RT, rotating. The samples were centrifuged at 850 £ g for 4 min at RT. The supernatant was discarded and the pellet was washed 4£, with ice cold PBS. SDS sample loading buffer was added to the pellet and boiled at 95 C for 5 min and analyzed by western blot.
Soft agar assay WT PTEN, Vetor, PTEN Y336*, and PTEN-HP1aKD reconstituted BT-549 cells (10,000 cells/plate) were resuspended in 0.35% agarose and seeded on 60 mm plates coated in 0.5% agarose. The cells were incubated for 26 d at 37 C, 5% CO 2 . Colonies were stained with a staining solution (0.005% crystal violet and 25% methanol in PBS) for visualization.
Lentiviral infection and siRNA transfection
MCF-10A PTEN knockdown (Psh) cells were generated by infecting with individual MISSION lentiviral particles (Sigma) targeting PTEN according to the manufacturer's instructions. After infection, cells were selected by using puromycin (1 mg/ml). BT-549 cells were generated by infecting with Vector, PTEN WT or PTEN Y336* lentiviral particles using the pLenti6/V5-DEST TM Gateway system (Invitrogen). After infection, cells were selected by using Blasticidin (10 mg/ml). PTEN-HP1aKD stable cells were generated by infecting BT549 PTEN WT stable cells with individual MISSION lentiviral particles (Sigma) targeting CBX5 according to the manufacturer's instructions. For transient transfection, PTEN was knocked down with siRNA (Sigma SASI_ Hs01_00196478 (Psi#1 5 0 GGUGUAAUGAUAUGUG-CAUdTdT) & Hs01_00196480 (Psi#2 5 0 CAAAUUUAAUUG-CAGAGUUdTdT)) using Lipofectamine 2000 or 3000 (Invitrogen) following the manufacturer's instructions. For mutant rescue experiments, U2OS cells were first transfected with control siRNA (control) or PTEN siRNA. After 24 h, cells were transfected with empty pLenti6.3 vector or various pLenti6.3-PTEN plasmids. Cells were harvested 24 h after the second transfection.
PI3K Inhibitor Treatment U2OS cells were transfected with PTEN siRNA using Lipofectamine 2000 following the manufacturer's protocol for 24 h. U2OS Psi cells and U2OS WT cells were serum starved for 4 h and treated with LY294002 (LY, 10 mM) for 3 h. The cells were harvested and analyzed by WB.
Heterochromatin Foci Staining
To observe heterochromatin foci, cells were cultured on cover slides and incubated with cytoskeleton buffer and then stripping buffer as previously described. 32 After fixation with 4% paraformaldehyde, cells were further permeabilized with ice-cold methonal/acetone (50:50) for 20 sec. The antibodies (anti-H3K9me3, Abcam #ab8898; anti-HP1a, Cell Signaling #2616; and anti-H3K4m2, Cell Signaling #9725) were diluted at 1:200 in 5% goat serum. The images were captured with an Olympus Fluo-ViewFV1000 confocal microscope.
Quantitative Reverse Transcription PCR Cells were harvested with Trizol (Invitrogen) according to the manufacturer's protocol. The SuperScript III First-strand Synthesis system (Invitrogen) kit was used for reverse transcription according the manufacturer's protocol. QPCR products were analyzed with SYBR green using Eppendorf RealPlex 4 detection system software. Cross-linking and ChIP were performed with a ChIP assay kit (Millipore). Primers used for qRT-PCR and qChIP are: Sata 5 0 AAGGTCAATGGCAGAAAAGAA, 5 0 CA ACGAAGGCCACAAGATGTC, mcBox 5 0 AGGGAATGTCT TCCCATAAAAACT, 5 0 GTCTACCTTTTATTTGAATTCC CG, MajorSat 5 0 GGCGAGAAAACTGAAAATCACG, 5 0 CTT GCCATATTCCACGTCCT, MinorSat 5 0 TTGGAAACGGGA TTTGTAGA, 5 0 CGGTTTCCAACATATGTGTTTT, HP1a (human) 5 0 TGGAAAGGCTTTTCTGAGGA, 5 0 ATGTCATC GGCACTGTTTGA, HP1a(mouse) 5 0 AGCCGACAGCTCT TCTTCAG, 5 0 CCCTGGGCTTATTGTTTTCA.
MNase Digestion Assay was conducted as described by. 33 Tissue arrays were obtained from US Biomax. After deparaffinization and antigen retrieval with citric acid, the slides were incubated with anti-PTEN (Cell Signaling #9188) and anti-HP1a (Cell Signaling #2616) antibodies. The final immunohistochemistry staining procedure was carried out using the LSAB2 System according to the manufacturer's protocol (Dako LSAB2 System-HRP).
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